Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | FLT3 D835delinsLK |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| FLT3 D835delinsLK | hematologic cancer | sensitive | Gilteritinib | Preclinical | Actionable | In a preclinical study, Xospata (gilteritinib) treatment inhibited Flt3 signaling and viability in a cell line expressing FLT3 D835delinsLK in culture and inhibited growth in a transplant model (PMID: 40196870). | 40196870 | |
| FLT3 D835delinsLK | hematologic cancer | decreased response | Quizartinib | Preclinical | Actionable | In a preclinical study, cells expressing FLT3 D835delinsLK were less sensitive to Vanflyta (quizartinib) compared to cells expressing a FLT3-ITD in culture and in a transplant model (PMID: 40196870). | 40196870 | |
| FLT3 D835delinsLK | hematologic cancer | sensitive | Midostaurin | Preclinical - Cell culture | Actionable | In a preclinical study, Rydapt (midostaurin) treatment decreased viability in a cell line expressing FLT3 D835delinsLK in culture (PMID: 40196870). | 40196870 |